Orex Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.10 Cr
as on 27-06-2024
- Paid Up Capital ₹ 2.29 Cr
as on 27-06-2024
- Company Age 45 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 41.94 Cr
as on 27-06-2024
- Revenue -1.53%
(FY 2023)
- Profit -38.08%
(FY 2023)
- Ebitda -22.51%
(FY 2023)
- Net Worth 15.69%
(FY 2023)
- Total Assets 1.14%
(FY 2023)
About Orex Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.10 Cr and a paid-up capital of Rs 2.29 Cr.
The company currently has active open charges totaling ₹41.94 Cr.
Kiran Pisal, Mangesh Pisal, and Baburao Pisal serve as directors at the Company.
- CIN/LLPIN
U99999MH1979PTC021403
- Company No.
021403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jun 1979
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Orex Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Baburao Pisal  | Managing Director | 20-Jun-1979 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kiran Pisal | Director | 01-Oct-2010 | Current |
| Mangesh Pisal | Director | 01-Oct-2004 | Current |
Financial Performance of Orex Pharma.
Orex Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.53% decrease. The company also saw a substantial fall in profitability, with a 38.08% decrease in profit. The company's net worth Soared by an impressive increase of 15.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orex Pharma?
In 2023, Orex Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Oct 2022 | ₹8.00 Cr | Open |
Others Creation Date: 10 Oct 2022 | ₹6.24 Cr | Open |
Others Creation Date: 10 Oct 2022 | ₹7.50 M | Open |
How Many Employees Work at Orex Pharma?
Orex Pharma has a workforce of 81 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
